

ISO/TS 10974:2018-04 (E)

Assessment of the safety of magnetic resonance imaging for patients with an active implantable medical device

Contents		Page
Foreword		vii
Introduction		viii
1	Scope	1
2	Normative references	1
3	Terms and definitions	1
4	Symbols and abbreviated terms	6
5	General requirements for non-implantable parts	6
6	Requirements for particular AIMDs	6
7	General considerations for application of the tests of this document	6
7.1	Compliance criteria	6
7.2	Use of tiers	7
7.3	Test reports	7
7.3.1	General	7
7.3.2	Description of the AIMD under test	7
7.3.3	Test methods and results	7
8	Protection from harm to the patient caused by RF-induced heating	8
8.1	Introduction	8
8.2	Outline of the Stage 1 four-tier approach	8
8.3	Measurement system prerequisites for all tiers	10
8.3.1	RF field source	10
8.3.2	Tissue simulating phantom	10
8.3.3	Definition of power deposition	12
8.3.4	Measurement system validation	12
8.4	Determination of RF-induced power deposition in a tissue simulating medium	12
8.4.1	General	12
8.4.2	Determine location of hot spots around the AIMD	13
8.4.3	Determination of spatial (3D) distribution of power deposition for each hot spot	13
8.4.4	Determine the final power deposition	14
8.5	Proximity effect of electrodes from multiple leads	16
8.6	Modelling prerequisites for Tier 2, Tier 3, and Tier 4	17
8.7	Tier selection for RF-induced power deposition	17
8.7.1	General	17
8.7.2	Tier 1	17
8.7.3	Tier 2	18
8.7.4	Tier 3	19
8.7.5	Tier 4	20
8.8	In vitro model validation	21
8.9	Overall uncertainty analysis	23
8.10	In vivo analysis of power deposition	24
8.11	RF-induced heating assessment flow chart	24
9	Protection from harm to the patient caused by gradient-induced device heating	27

9.1	Introduction	27
9.2	Testing considerations	28
9.2.1	General	28
9.2.2	Determination of $ dB/dt $ rms exposure limits	29
9.2.3	Determination of test duration	29
9.3	Test requirements	29
9.3.1	General	29
9.3.2	In vitro test phantom or other suitable container	30
9.3.3	Gelled solution	30
9.3.4	Temperature survey to determine orientation and hot spots	30
9.3.5	Minimum temperature instrumentation	31
9.3.6	Definition of dB/dt test waveform	31
9.3.7	Characterization of applied dB/dt	32
9.4	Lab testing using simulated MR gradient field	32
9.5	MR scanner testing	32
9.6	Analysis of gradient heating test	33
10	Protection from harm to the patient caused by gradient-induced vibration	33
10.1	Introduction	33
10.2	Overview of tiers	34
10.3	MR environmental conditions	35
10.3.1	General	35
10.3.2	Determination of maximum clinical dB/dt	35
10.3.3	Determination of clinical B0	35
10.3.4	Determination of clinical dB/dt \times B0	35
10.3.5	Test frequencies	35
10.3.6	Test duration	36
10.3.7	Test temperature	37
10.4	General test procedure	37
10.4.1	Measurement of gradient field and determination of AIMD location	37
10.4.2	AIMD/test unit setup	37
10.5	Method 1 -- MR scanner	38
10.6	Method 2 -- Shaker table	39
10.6.1	General	39
10.6.2	Determine scanner input	39
10.6.3	AIMD vibration response	39
10.6.4	Determine shaker table amplitude (dB/dt scaling)	40
10.6.5	Perform vibration exposure using a shaker table	40
11	Protection from harm to the patient caused by B0-induced force	41
12	Protection from harm to the patient caused by B0-induced torque	41
13	Protection from harm to the patient caused by gradient-induced extrinsic electric potential	41
13.1	Introduction	41
13.2	General requirements	42
13.3	Gradient pulse leakage test	46
13.3.1	General	46
13.3.2	Test equipment	46
13.3.3	Test signal	46
13.3.4	Tier 1 -- Combined gradient-induced charge measurement test procedure	48
13.3.5	Tier 2 -- Separate transient gradient-induced charge and steady-state current measurement test procedure	51
13.4	Gradient rectification test	53
13.4.1	General	53
13.4.2	Test equipment	53
13.4.3	Test signal	53
13.4.4	Gradient-induced rectification measurement test procedure	54
13.5	Gradient pulse distortion of AIMD output test	56
13.5.1	General	56

13.5.2	Test equipment	56
13.5.3	Test signal	56
13.5.4	Gradient-induced AIMD output distortion test procedure	56
14	Protection from harm to the patient caused by B0-induced malfunction	58
14.1	Introduction	58
14.2	Static field testing	59
14.2.1	B0 general requirements for static field testing	59
14.2.2	B0 field generation	60
14.2.3	Test conditions	60
14.3	Test procedures	60
14.3.1	General	60
14.3.2	Class 0 test procedure	60
14.3.3	Class 1 test procedure	60
14.3.4	Class 2 test procedure	61
15	Protection from harm to the patient caused by RF-induced malfunction and RF rectification	61
15.1	Introduction	61
15.2	General requirements	61
15.3	Mechanisms for RF interaction with an AIMD	61
15.4	Selecting radiated vs injected test methods	63
15.4.1	General	63
15.4.2	AIMD type designation for test method selection	63
15.4.3	RF antenna type designation for test method selection	65
15.4.4	RF EMC tier selection	65
15.4.5	RF test conditions	65
15.4.6	B0 considerations	68
15.5	Injected immunity test	68
15.5.1	General	68
15.5.2	Determination of peak and rms injected levels for Tier 1 and Tier 2 -- AIMD with short electrical length	69
15.5.3	Determination of peak and rms injected levels for Tier 3 and Tier 4	69
15.5.4	Injected immunity test procedure	71
15.5.5	RF phase test conditions	71
15.5.6	AIMD monitoring during the test	72
15.6	Radiated immunity test	72
15.6.1	General	72
15.6.2	Determining the RF radiated field level	72
15.6.3	Radiated test procedure	72
15.6.4	AIMD monitoring during the test	73
15.7	Test equipment	73
15.7.1	Generating the RF electric field for radiated testing (AIMD with short electrical length)	73
15.7.2	Phantom and tissue simulating medium for radiated testing	73
15.7.3	AIMD monitoring apparatus	73
15.7.4	RF level measuring device	74
15.7.5	RF injection network	74
15.8	Determining the peak RF injected level using a radiated test	75
16	Protection from harm to the patient caused by gradient-induced malfunction	76
16.1	Introduction	76
16.2	General requirements	76
16.3	Selecting radiated and injected test methods	77
16.4	Radiated immunity test	78
16.4.1	General	78
16.4.2	Test equipment	78
16.4.3	Radiated test signal	79
16.4.4	Test procedure	81
16.5	Injected immunity test	82
16.5.1	General	82
16.5.2	Test equipment	82
16.5.3	Injected test signal	82

16.5.4	Test procedure	84
16.5.5	AIMD test configuration	86
17	Combinedfieldstest	93
17.1	Introduction	93
17.2	Test setup	94
17.3	AIMD fixation	96
17.4	Test procedure	97
17.4.1	General	97
17.4.2	Before MR exposure	97
17.4.3	During MR exposure	97
17.4.4	After MR exposure	97
17.5	Test equipment	97
17.5.1	Field generation	97
17.5.2	Phantom and tissue simulating medium	97
17.5.3	AIMD monitoring apparatus	98
18	Markings and accompanying documentation	98
18.1	Definitions	98
18.2	Applicability of labelling requirements	98
18.3	Labelling requirements	98
Annex A (normative) Pulsed gradient exposure for Clause 10, Clause 13, and Clause 16		100
Annex B (informative) Derivation of lead length factor for injected voltage test levels for Clause 13 and Clause 16		112
Annex C (informative) Tier 1 high tangential E-field through liner resonator		121
Annex D (informative) Supporting information and rationale for gradient-induced device heating .		128
Annex E (informative) Example RF injection network		133
Annex F (informative) Supporting information and rationale for MR-induced vibration		135
Annex G (informative) Gradient vibration patent declaration form		139
Annex H (informative) Assessment of dielectric and thermal parameters		141
Annex I (informative) RF exposure system validation method		146
Annex J (informative) MR scanner RF transmit coil		156
Annex K (informative) Current distribution on the AIMD as a function of the phase distribution of the incident field		158
Annex L (informative) Tissue simulating medium formulations		161
Annex M (informative) Generation of incident fields		165
Annex N (informative) Dielectric and thermal tissue properties		180
Annex O (informative) Gradient field injected testing -- AIMD electrode tissue impedance determination method		184
Annex P (informative) Estimation of conservative B ₁ and 10 g averaged E-field values for Tier 1 for RF- induced heating and RF malfunction		189
Annex Q (informative) AIMD configuration		197
Annex R (informative) Electrically excitable tissue stimulation, terms and definitions		198

Annex S (informative) Combined field test200
Annex T (informative) General methods for modelling dB/dt levels in MR gradient coils206
Bibliography212